Your scientific partner for drug and in-vitro diagnostic development.
Pacific Biomarkers is a biomarker testing services provider, supporting pharmaceutical, biotech and in-vitro diagnostic (IVD) manufacturing companies through preclinical and Phase I-IV studies of drug and IVD development.
Pacific Biomarkers has an established reputation for expertise, flexibility, protocol consultation, and outstanding client services that has propelled the company to a prominent position in the rapidly growing pharmaceutical outsourcing industry. With over 300 fully CLIA validated assays and an extensive network of scientific, regulatory, and technology expertise, Pacific Biomarkers is the service provider of choice for many leading international drug manufacturers in the race to bring products to market as quickly and cost effectively as possible.
Pacific Biomarkers provides accurate, reliable analyses, and responsive service to sponsors and investigative sites. Pacific Biomarkers collaborates with sponsors to develop, validate, improve analytical methods, and provide technical consultation for protocol design. Our services are customized on a project specific basis which allows Pacific Biomarkers to be more flexible to meet the needs of our clients.
Pacific Biomarkers is a CAP accredited and CLIA certified laboratory. Pacific Biomarkers also provides GLP compliant biomarker laboratory services.
Originally named Pacific Biometrics, Inc., Pacific Biomarkers was founded in 1989 as a spin-off from the University of Washington Lipid Research Center, Dept. of Medicine. Founders Dr. Elizabeth Leary and Russ Warnick had a vision for global standardization of lipid testing. When the CDC initiated the Cholesterol Reference Method Laboratory Network (CRMLN), Pacific Biomarkers became a member of this network: three labs in the U.S. and 11 globally. For 20 years, Pacific Biomarkers provided lipid reference and standardization services for in-vitro diagnostic manufacturers and clinical laboratories.
During this time, Pacific Biomarkers began consulting with pharmaceutical companies to support drug development. This clinical trial support has now become a core business of the company. Traditionally, our therapeutic focus has been cardiovascular and musculoskeletal diseases, diabetes, obesity, metabolic syndrome, and inflammation. Today, we have evolved to meet the needs of our customers, providing biomarker support across a wide range of therapeutic areas.
In 2007, Pacific Biomarkers expanded its capabilities into immunogenicity testing, cell based assay services, and novel biomarker development. Shortly after in 2009, Pacific Biomarkers officially changed its name to Pacific Biomarkers to better reflect our business. In an effort to expand our clinical trial testing to Asia, Pacific Biomarkers partnered with Syngene International Ltd. and Wuxi AppTech in 2011 and 2014, respectively. Through these strategic collaborations, we can offer our 300+ CLIA validated biomarkers across diverse therapeutic areas in Asia with added capabilities within immunogenicity and cell based functional assays in a cost effective business model.
More recently in 2015, we introduced the Pacific Biomarkers Mobile App; an interactive platform that provides access to innovative tools such as the BIOMARKER NAVIGATOR and allows you to create biomarker information reports instantly from our broad biomarker testing menu.
Built in 2012 from a cold shell, we have completely customized over 21,000 sq. ft. of expandable space including a CAP/CLIA certified laboratory.